Eli Lilly Makes Bold $2.4 Billion Bet on Revolutionary In Vivo CAR-T Technology with Orna Therapeutics Acquisition

In a transformative move that signals Eli Lilly's ambitious expansion into cutting-edge cell therapy, the pharmaceutical giant announced on February 9, 2026, its agreement to acquire Orna Therapeutics for up to $2.4 billion in cash. This landmark deal positions Lilly at the forefront of a revolutionary approach to treating autoimmune diseases through in vivo CAR-T therapy, potentially reshaping how patients receive life-changing cell treatments.

The acquisition centers on Orna's groundbreaking circular RNA platform paired with novel lipid nanoparticles, technology that allows patients' own bodies to generate therapeutic cells without the complex, costly manufacturing processes that have limited traditional CAR-T therapies. For Lilly, this represents a strategic entry into the rapidly evolving cell therapy space, complementing its established expertise in immunology and metabolic diseases.

Breaking Down Barriers in Cell Therapy

Traditional CAR-T therapies, while revolutionary in treating certain blood cancers, face significant limitations that have restricted their broader application. These ex vivo approaches require extracting a patient's T cells, genetically modifying them in specialized facilities, and then reinfusing them back into the patient. This process is not only expensive and time-consuming but also logistically challenging, limiting access for many patients who could benefit from cell therapy.

Orna's in vivo approach fundamentally changes this paradigm. Using engineered circular RNA delivered through sophisticated lipid nanoparticles, the therapy instructs the patient's own immune cells to transform into therapeutic CAR-T cells directly within the body. This eliminates the need for cell extraction, external manufacturing, and complex supply chain logistics that have made traditional CAR-T therapies accessible to only a fraction of patients who could benefit.

"Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost, and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them," said Francisco Ramírez-Valle M.D., Ph.D., Senior Vice President, Head of Immunology Research and Early Clinical Development at Lilly.

Circular RNA: The Next Generation of Genetic Medicine

At the heart of Orna's technology lies circular RNA, a sophisticated evolution beyond traditional messenger RNA approaches. Unlike linear mRNA, which degrades relatively quickly in the body, circular RNA forms a closed loop structure that provides enhanced stability and potentially longer-lasting therapeutic effects. This durability could be crucial for applications requiring sustained protein expression, such as generating and maintaining therapeutic CAR-T cells over extended periods.

Orna's circular RNA platform offers several advantages over conventional approaches. The simplified production process could reduce manufacturing costs and complexity, while improved formulation into lipid nanoparticles may enhance delivery efficiency. Most importantly, the superior protein expression achieved by circular RNA could unlock treatments that are simply not feasible with current RNA or cell therapy platforms.

The company's lead program, ORN-252, exemplifies this potential. This clinical trial-ready therapy targets CD19, a protein found on B cells that plays a crucial role in various autoimmune diseases. By programming patients' T cells to recognize and eliminate problematic B cells, ORN-252 could potentially reset the immune system and provide long-lasting relief for patients with conditions like lupus, rheumatoid arthritis, and multiple sclerosis.

Strategic Rationale for Lilly's Bold Investment

For Lilly, the Orna acquisition represents more than just entry into cell therapy; it's a strategic bet on the future of precision medicine. The company has been building significant expertise in immunology, with breakthrough therapies like litifilimab for cutaneous lupus erythematosus recently receiving FDA Breakthrough Therapy Designation. Adding Orna's in vivo CAR-T platform creates synergies that could accelerate development across multiple autoimmune indications.

The $2.4 billion price tag, structured as an upfront payment plus milestone-based payments, reflects both the transformative potential of the technology and the competitive landscape for innovative cell therapy platforms. This investment level demonstrates Lilly's confidence that in vivo CAR-T therapy could become a cornerstone of autoimmune disease treatment, potentially generating billions in revenue while serving patients who currently have limited treatment options.

The timing of this acquisition is particularly strategic. While traditional CAR-T therapies have proven their efficacy in blood cancers, their application to autoimmune diseases represents a newer frontier with enormous potential. Early clinical studies have shown promising results, but the logistical challenges of ex vivo manufacturing have limited broader development. Orna's in vivo approach could unlock this potential by making cell therapy more accessible and scalable.

Market Implications and Competitive Landscape

Lilly's acquisition of Orna positions the company to compete directly with other pharmaceutical giants investing heavily in cell therapy. Companies like Bristol Myers Squibb, Gilead Sciences, and Johnson & Johnson have made significant investments in CAR-T technology, but most have focused on traditional ex vivo approaches. Lilly's bet on in vivo technology could provide a competitive advantage if the approach proves successful in clinical trials.

The autoimmune disease market represents a massive opportunity, with conditions like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease affecting millions of patients worldwide. Current treatments, while effective for many patients, often require lifelong therapy and may lose effectiveness over time. A one-time or infrequent cell therapy that could provide durable remission would represent a paradigm shift in treatment approaches.

From a financial perspective, successful development of Orna's platform could generate substantial returns on Lilly's investment. Cell therapies typically command premium pricing due to their transformative potential, with some CAR-T therapies priced at several hundred thousand dollars per treatment. If Orna's in vivo approach can deliver similar efficacy with improved accessibility and reduced manufacturing costs, it could capture significant market share while serving more patients.

Scientific and Regulatory Challenges Ahead

Despite the promising potential, significant challenges remain in translating Orna's technology into approved therapies. In vivo CAR-T therapy represents a relatively new approach, and regulators will likely require extensive safety and efficacy data before approval. Questions about durability of response, potential off-target effects, and optimal patient selection will need to be addressed through rigorous clinical trials.

The complexity of autoimmune diseases also presents unique challenges. Unlike blood cancers, where CAR-T therapies target malignant cells, autoimmune applications require more nuanced approaches to avoid excessive immune suppression while achieving therapeutic benefit. Orna's CD19-targeting approach has shown promise in early studies, but larger trials will be needed to establish optimal dosing, patient selection criteria, and long-term safety profiles.

Manufacturing and quality control for circular RNA and lipid nanoparticle formulations will also require careful attention. While potentially simpler than traditional CAR-T manufacturing, these technologies still require sophisticated production capabilities and rigorous quality standards to ensure consistent therapeutic outcomes.

Looking Ahead: Transforming Autoimmune Disease Treatment

The integration of Orna's team and technology into Lilly's broader immunology portfolio creates exciting possibilities for accelerated development and expanded applications. Lilly's established clinical development capabilities, regulatory expertise, and global commercial infrastructure could help bring Orna's innovations to patients more quickly than might be possible as a standalone company.

Beyond the lead ORN-252 program, Orna's platform technology could potentially be adapted for other autoimmune conditions, different target antigens, or even applications beyond autoimmune disease. The flexibility of the circular RNA approach suggests multiple development pathways that could maximize the value of Lilly's investment while serving diverse patient populations.

For patients with autoimmune diseases, this acquisition represents hope for fundamentally new treatment approaches. If successful, in vivo CAR-T therapy could offer the possibility of durable remission with a single treatment, eliminating the need for lifelong immunosuppressive therapy and dramatically improving quality of life.

As Joe Bolen, Ph.D., CEO of Orna Therapeutics, noted: "We are excited to join forces with Lilly, an industry leader in the development of patient-centric therapeutics to realize the full potential of these technologies." This collaboration between Orna's innovative platform and Lilly's development expertise could indeed unlock entirely new classes of genetic medicines and cell therapies.

The success of this ambitious acquisition will ultimately be measured not just in financial returns, but in its ability to transform treatment for millions of patients worldwide living with autoimmune diseases. As Lilly integrates Orna's revolutionary technology, the pharmaceutical industry will be watching closely to see whether in vivo CAR-T therapy can deliver on its transformative promise.